Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Euro Ewing 2012
ISRCTN92192408Phase 3Completed
- Sponsor
- University of Birmingham
- Start
- Dec 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of vincristine, ifosfamide, doxorubicin, etoposide, actinomycin D and 4 more in Ewing sarcoma (8 arms), sponsored by University of Birmingham. Primary endpoint: Event-free survival. Started Dec 2013; status: completed.
02
Drugs
vincristineifosfamidedoxorubicinetoposideactinomycin D
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on ISRCTN92192408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN92192408.